In the CCl4-induced liver fibrosis group, angiotensin II promoted the production of VEGF, while olmesartan dramatically reduced angiotensin II-induced VEGF production (Figure 6(c)). The gene discussed is VEGFA; the disease is Hepatic fibrosis.